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332* Validation of the treatment satisfaction questionnaire for
medication (TSQM) in cystic ﬁbrosis (CF)
A. Regnault1, M.-M. Balp2, K. Kulich3, L. Este`ve1, M. Viala-Danten1. 1Mapi
Values, Psychometrics & Statistics, Lyon, France; 2Novartis, HEOR Respiratory,
Basel, Switzerland; 3Novartis, Basel, Switzerland
Objectives: To assess the measurement properties of the TSQM, a 14-item ques-
tionnaire measuring 4 dimensions related to treatment satisfaction (Effectiveness;
Side-effects; Convenience; Global satisfaction) in CF.
Methods: The TSQM is a generic treatment satisfaction instrument validated in
several chronic diseases but not used before in CF. It was included in the EAGER
study, a randomized open-label clinical trial comparing a nebulized and a dry
powder device for inhaled tobramycin in a CF population aged 6 years and above.
The two treatment arms (N= 553) were pooled together to conduct psychometric
analyses. Construct validity was assessed using conﬁrmatory factor analysis (CFA)
and multi-trait analysis. Cronbach’s a were calculated to assess internal consistency
reliability. Differential item functioning between responders who were assisted by
a relative (patients below 12 years of age) and those who were not was sought for
using logistic regression.
Results: The quality of completion of the 14 TSQM items was excellent since
all had less than 2% missing data. The CFA goodness-of-ﬁt of the 4-dimension
structure met commonly used standards (e.g. Goodness of Fit index = 0.92). In
the multitrait analysis, all items met the convergent validity criterion and all but
one met the discriminant validity. All Cronbach’s a were above 0.86, indicating
very good reliability for all 4 dimensions. No item showed differential functioning
related to mode of administration (alone vs. with the assistance of a relative).
Conclusion: The TSQM showed excellent measurement properties that strongly
support the use of this instrument to assess patient satisfaction with inhaled
CF treatments.
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Respiratory function is an indicator of disease progression in patients with CF.
Education is essential when involving patients in their treatment.
Objective: to consider patient understanding of respiratory function tests (RFT’s)
when given information graphically and if this would impact on their adherence to
treatment.
Method: 26 CF patients (12 male) completed a questionnaire evaluating under-
standing of their RFT’s (speciﬁcally FEV1). Following presentation of their FEV1
trend over the previous year as numbers and graphs, the questionnaire was repeated.
100% of patients wanted information on respiratory function. 88% of patients rated
importance of RFT’s as greater than 70% on a visual analogue scale. 50% of
patients felt they knew their FEV1 measurement. 76% correctly identiﬁed their
FEV1 with 19% correctly identifying their trend following presentation of the graph
suggesting greater understanding of information given. When greater understanding
of data occurred, 65% reported to prefer graphs as compared to numbers, 50% of
patients consider that their adherence to therapies would increase. 27% were unsure
if additional information would alter their behaviour. Patients identifying respiratory
function as low in importance also experienced the lowest FEV1. Education is
essential when motivating patients.
Conclusion: Respiratory function can be preserved with adherence to airway
clearance, exercise and nebulisers if we optimise education. In line with patient
choice respiratory function data will be given in the desired format at clinic.
Presentation of respiratory data, in numbers or graphs can inﬂuence treatment
behaviour, may improve adherence and effect quality of life.
334* Attitudes and barriers to the implementation of new E-health
strategies in cystic ﬁbrosis (CF)
J.W. Wilson1, H. Ambrose1, M. Braithwaite1. 1Alfred Hospital, Allergy, Immunology
and Respiratory Medicine, Melbourne, Australia
Opportunities for better healthcare have arisen because of advances in technology.
Barriers and entrenched beliefs may impede the implementation of strategies in
E-health.
Aim: To identify staff and patient barriers to implementation and use of new E-health
applications.
Methodology: Thematic analysis of focus groups (patients n = 5, staff n = 5) identiﬁed
ﬁve themes (1) current usage, (2) barriers, (3) attitudes, (4) beneﬁts and (5) current
systems. A staff and patient survey was developed based on the ﬁve domains.
Individual’s responses were scored from 0−10 on a Likert scale (5 = indeterminate
response).
Results: A total of 267 participants (130 patients, mean age 32.87±10.49 years (50.0%
males) and 137 staff, mean age = 32.25±10.51 years (33.7% males) completed the
survey. Perceived barriers to E-health effectiveness are shown in table 1. Perceived
beneﬁts of technology are shown in table 2. Participants (54% staff, 68% patients) are
more comfortable with a password-protected electronic health record compared to the
current paper-based system.
Conclusion: (1) Training, security and funding issues must be addressed, (2) Change
management strategy required − policy development
Table 1: Top 5 identiﬁed barriers to the implementation of E-health strategies
Barriers Patients (Mean±SD) Staff (Mean±SD) p Value
Funding 7.48±2.60 5.76±2.99 <0.01
Privacy/security concerns 7.48±2.62 3.55±2.48 <0.01
Lack of training/support 7.11±2.63 4.69±2.70 <0.01
Age of computer 6.46±3.02 5.50±3.11 <0.05
Slow/inadequate internet access 6.15±3.05 5.53±3.04 NS
Table 2: Beneﬁts of SMS, videoconferencing and telemedicine reminders
Patient Staff
SMS appointment reminders beneﬁcial to patients 7.87±2.93 7.24±2.50 NS
Video conferencing beneﬁcial to me 5.55±2.86 5.80±2.69 NS
SMS medication reminders beneﬁcial to me 5.99±2.97 6.00±2.86 NS
335 Improving patient satisfaction by using PICC for intravenous
antibiotic therapy
E. Veldhoen1, M. Kok1, A. van Dijk1, R. Wensing2, H.G.M. Arets3. 1UMC
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Introduction: Since January 2010 pediatric CF patients requiring intravenous (iv)
antibiotic therapy are offered a Peripherally Inserted Central Catheter (PICC) instead
of a venﬂon. One year after introduction the procedure was evaluated.
Methods: PICC insertion occurs ultrasound guided using the Modiﬁed Seldinger
technique. Some patients received oxazepam prior to the procedure; subcutaneous
lidocain was given as a local analgetic. Demographic data of all CF patients
receiving a PICC and complications were prospectively registered in a database.
We contacted all patients after discharge to evaluate complications and patient
satisfaction.
Results: PICC insertion was attempted in 49 patients. In 2 cases insertion of PICC
was unsuccessful, both in the 1st trimester after start of the project. 9 CF patients
received a PICC during two or more treatment periods. Median age of patients
13 years (range 6−18). Median duration of PICC presence was 17 days (range 2−51).
One patient had a swollen arm, without any evidence for thrombosis on radiological
examination; one PICC was occluded and damaged, after an attempt to resolve
occlusion. No infections were seen, nor proven thrombosis. Patient satisfaction was
high, mainly based on reduced stress compared to repeatedly inserted venﬂons in
the past and less mobility restrictions. All patients would prefer a PICC in the
future.
Conclusion: PICCs are useful alternatives for iv treatment of CF patients. Success
rates are high, complication rate is low and patient satisfaction increased since
introduction. This supports continuation of our PICC team.
